Avacta Shares Rose 2.2% on an Upcoming Conference Presentation

The Avacta Group Plc (LON: AVCT) share price rose 2.2% after announcing that it would be presenting promising new data from the pre|CISION^TM  and Affimer® platform assets at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

The data presented at the conference will be regarding AVA3996, a FAP-α-activated proteasome inhibitor from the pre|CISION^TM platform that concentrates proteasome inhibitor payload in the tumour while increasing the therapeutic index of this class of drugs. 

The company will also present data about AVA032, an anti-PD-L1 Affimer® fused to IL-15, which has demonstrated encouraging in vitro and in vivo efficacy. Therefore, Avacta will be presenting two posters at the conference that will be taking place from 11-15 October 2023 in Boston, Massachusetts.

The abstract titles of the two posters are: “AVA3996, a novel pre|CISION™ medicine, targets a warhead to the tumour microenvironment via Fibroblast Activation Protein (“FAP”) mediated cleavage to elicit tumour cell kill”  and “A novel, tumour-targeted immunocytokine comprising an anti-PD-L1 Affimer® fused to IL-15 exhibits potent anti-tumour activity”.

Avacta’s Chief Scientific Officer, Dr Fiona McLaughlin, commented: “We look forward to presenting the promising new data from Avacta's Therapeutics platform assets at this conference. As disclosed in the Company's announcement on 19 September 2023, our lead asset, AVA6000, continues to advance through the clinic at pace. We are simultaneously conducting IND-enabling studies for promising assets derived from the pre|CISION^TM and Affimer® platforms. The data to be presented showcases the potential of our two therapeutic platforms to generate further high-value clinical assets.”

She added: “AVA3996, a FAP-α-activated proteasome inhibitor based on our pre|CISION^TM technology, demonstrates targeted killing of cancer cells in vitro and, by concentrating the active warhead in the tumour, reduces systemic toxicity associated with this class of drug.”

“AVA032, our anti-PD-L1 Affimer® fused to the pro-inflammatory cytokine interleukin 15 (IL-15), displays encouraging efficacy when tested in multiple models of immunomodulation, stimulating a potent immune response and reversing the immunosuppressive tumour microenvironment.”

Avacta share price. 

The Avacta share price rose 2.2% to trade at 127.75p, from Wednesday’s closing price of 125.00p.